Business Overview: Organon & Co. (NYSE: OGN)

---

Executive Summary

Organon & Co. is a global healthcare company spun off from Merck & Co. in June 2021, separating Merck's portfolio of off-patent, slower-growth medicines and its women's health franchise from Merck's patent-protected, innovation-driven oncology and vaccines business. Organon sells more than 70 products in over 140 countries and territories, generating roughly $6.2 billion in 2025 revenue, about 74% of it outside the United States.

Organon matters to the healthcare landscape as the world's largest standalone women's health company by revenue scale, the owner of a broad established brands portfolio (cardiovascular, respiratory, dermatology, and other legacy medicines that have mostly lost patent exclusivity), and a growing biosimilars business that competes on price against expensive originator biologics in immunology and oncology. Unlike its former parent, Organon's moat does not rest on patent-protected blockbusters — it rests on manufacturing scale, regulatory know-how, prescriber habit, and global commercial infrastructure built to sustain a large, mature, and partly declining product base.

Since the spinoff, Organon has carried a heavy debt load inherited to fund the separation, which has shaped nearly every strategic decision since: an ~90% dividend cut in 2025 (from $0.28 to $0.02 per share quarterly) to redirect cash toward deleveraging, continued divestitures (e.g., the Jada postpartum hemorrhage system, sold to Laborie in January 2026), and disciplined cost management rather than aggressive M&A. The central investment question is whether biosimilars growth and women's health stability can offset structural decline in established brands quickly enough to bring leverage down to management's target.

---

1. Core Business Model & How They Work

Organon's economics differ fundamentally from a research-driven innovator pharma. It does not depend primarily on new drug discovery; instead, it monetizes already-approved, often off-patent assets at scale, supplemented by a biosimilars pipeline that re-engineers the economics of expensive biologics.

[ Acquire/Inherit Mature or Off-Patent Assets ]
            ➡️
[ Global Manufacturing (6 owned sites) + Regulatory Maintenance ]
            ➡️
[ Commercialize via Wholesalers, Hospitals, Retailers, Government Payers in 140+ Countries ]
            ➡️
[ Durable but Declining Branded Revenue (Established Brands) ]
            +
[ Specialty Women's Health Products with Clinical Switching Friction ]
            +
[ Biosimilars Priced Below Originator Biologics to Win Share ]

Key Operational Drivers

1. Mature Portfolio Monetization: Most Established Brands products (e.g., Zetia, Singulair, Fosamax) have lost patent exclusivity and face generic competition; Organon extracts cash flow from prescriber habit, trusted branding, and distribution reach rather than legal exclusivity, which is why revenue in this segment declines a few percent per year rather than growing.
2. Women's Health Specialization: Nexplanon (a long-acting reversible contraceptive implant) and other contraception/fertility products benefit from genuine clinical and behavioral switching costs — once a patient and physician have committed to a device or regimen, switching involves real procedural friction.
3. Biosimilars as a Growth Lever: Organon partners with Samsung Bioepis and Henlius to commercialize biosimilar versions of blockbuster biologics (e.g., Hadlima/adalimumab, Renflexis/infliximab, Ontruzant/trastuzumab), competing primarily on price once the originator's exclusivity lapses — this is the one segment growing revenue (+4% in 2025).
4. Capital-Light Manufacturing Footprint: Organon owns six manufacturing sites (Brazil, UK, Belgium, Netherlands, Indonesia, Mexico) and leans on third-party contract manufacturers for drug substance, keeping fixed capital intensity manageable relative to its revenue base.
5. Deleveraging as the Dominant Capital Allocation Priority: With debt of roughly $8.6 billion against ~$574 million of cash at year-end 2025, free cash flow generation is directed first toward reducing net leverage (management's target: below 4.0x), not growth investment or shareholder returns.

---

2. Business Segments

Organon reports results across Women's Health, Biosimilars, and Established Brands (the latter two grouped under "General Medicines" in SEC filings), plus a small "Other" category.

┌────────────────────────────────────────────────┐
│              Organon & Co. — FY2025             │
│           Total Revenue: ~$6.2 billion          │
└─────────────────────┬────────────────────────────┘
                       │
   ┌───────────────────┼─────────────────────┬──────────────┐
   ▼                   ▼                     ▼              ▼
┌─────────────┐   ┌─────────────┐   ┌───────────────────┐  ┌───────┐
│ Women's     │   │ Biosimilars │   │ Established Brands│  │ Other │
│ Health      │   │             │   │                    │  │       │
│ ~28% / $1.75B│  │ ~11% / $0.69B│  │ ~59% / $3.69B      │  │ ~1%   │
│ (1)% YoY    │   │ +4% YoY     │   │ (4)% YoY           │  │(28)%  │
└─────────────┘   └─────────────┘   └───────────────────┘  └───────┘

Women's Health (~28% of revenue, ~$1.75B): Anchored by Nexplanon/Implanon (contraceptive implant), NuvaRing, and the fertility franchise (Follistim AQ, Elonva, ganirelix acetate). Roughly half of this segment's revenue is generated outside the U.S. Organon divested the Jada postpartum hemorrhage system to Laborie in January 2026, narrowing the segment slightly going forward, and continues to pursue label expansions (Nexplanon's five-year duration label was approved in January 2026).

Biosimilars (~11% of revenue, ~$0.69B): The fastest-growing segment, up 4% in 2025. Immunology biosimilars (Hadlima, Brenzys, Renflexis, Tofidence) and oncology biosimilars (Ontruzant, Aybintio, Bildyos/Bilprevda, and the newly approved Poherdy) compete against originator biologics and rival biosimilar makers on price, supported by manufacturing and regulatory partnerships with Samsung Bioepis and Henlius.

Established Brands (~59% of revenue, ~$3.69B): The largest but structurally declining segment (down 4% in 2025), spanning cardiovascular (Zetia, Vytorin, Atozet, Cozaar/Hyzaar, ~$1.1B), respiratory (Singulair, Dulera, Asmanex, Nasonex, Clarinex, ~$842M), dermatology/bone health/non-opioid pain (Vtama, Fosamax, Arcoxia, ~$987M), and other legacy brands (Emgality, Proscar, Propecia, ~$726M). The vast majority of this revenue (~91%) comes from outside the U.S., where branded pharmaceuticals retain pricing and prescribing stickiness longer after losing U.S. exclusivity.

---

3. Product Portfolio

---

4. Competitive Landscape

Women's Health: Organon competes against Bayer (Mirena, Kyleena IUDs, Yaz/Yasmin), Pfizer (various contraceptive and fertility products), and specialty women's health players. Organon's scale advantage lies in having the broadest global LARC and contraception portfolio among specialized women's health competitors, though Bayer's IUD franchise is a direct and well-entrenched rival to Nexplanon in the LARC category.

Biosimilars: This is the most crowded and price-competitive arena. Sandoz (the largest pure-play biosimilars company globally), Pfizer (through its Hospira biologics heritage), Samsung Bioepis (also Organon's manufacturing/commercialization partner on several products, making it both partner and indirect competitor on others), and Celltrion all compete to be first-to-market and lowest-cost on each new biosimilar opportunity. Competitive success in biosimilars depends on manufacturing cost discipline, regulatory interchangeability designations, and payer/PBM formulary positioning rather than brand loyalty.

Established Brands: Because most products have lost exclusivity, Organon's true competitors are often generic manufacturers — Teva, Viatris, and regional generics players — rather than other branded pharma companies. Organon's advantage versus pure generics makers is retained brand recognition and physician habit in many ex-U.S. markets, where branded-generic distinctions still carry weight with prescribers and patients even after a molecule's patent has expired.

---

5. Strategic Strengths & Risks

Moat Sources

• Prescriber Habit and Brand Recognition: Decades-old brand names (Fosamax, Singulair, Zetia) retain prescribing inertia in many ex-U.S. markets long after patent expiry — a soft but real moat distinct from legal exclusivity.
• Regulatory and Manufacturing Know-How: Operating six owned manufacturing sites and navigating complex, multi-jurisdictional regulatory maintenance (including for biosimilars, which require extensive analytical and clinical comparability data) is a genuine barrier to entry that smaller players cannot easily replicate.
• Clinical Switching Friction in Women's Health: LARC devices like Nexplanon require a clinical procedure to insert and remove, creating real patient and provider switching costs that a simple pill substitution would not.
• Interchangeability Designations: Hadlima's FDA interchangeability status across all presentations is a specific, defensible regulatory advantage over biosimilar rivals lacking that designation.

Key Risks

• Heavy Debt Load from the Spinoff: Organon inherited approximately $8.6 billion in debt at year-end 2025 against limited cash, with leverage near or above management's 4.0x target — this constrains capital allocation and was the direct cause of the 2025 dividend cut.
• Structural Decline in Established Brands: The largest segment (~59% of revenue) is shrinking annually (down 4% in 2025) as off-patent products face ongoing generic erosion, with no internal pipeline replacing that lost volume.
• Biosimilar Pricing Competition: Biosimilars succeed by undercutting originator prices, which caps segment margins even as volumes grow, and new entrants can further compress pricing once multiple biosimilars exist for the same reference product.
• Patent Cliffs on Core Assets: Nexplanon's U.S. rod patents expire in 2027 (applicator patents to 2030), with active litigation from generic challenger Xiromed — a potential future hole in the Women's Health segment's most important product.
• Policy and Pricing Pressure: U.S. Inflation Reduction Act price negotiations (effective 2026–2027), elimination of the Medicaid rebate cap, EU reference pricing, China's volume-based procurement (VBP) rounds that have cut prices over 50% on average, and potential new pharmaceutical tariffs all pressure realized pricing globally.
• Governance/Controls Issue: An Audit Committee review opened in February 2026 into the timing of biosimilar purchases from a supplier, alongside disclosed material weaknesses in internal controls, adds near-term uncertainty, though the company has stated it expects to file its 2025 Form 10-K on time and has not found anything inappropriate to date.

---

6. Financial Overview

All figures sourced from Organon's FY2025 10-K and Q4/FY2025 earnings release; leverage ratio is an approximate calculation based on disclosed debt, cash, and Adjusted EBITDA figures, not a company-reported multiple.

---

7. Summary Conclusion

Organon is best understood as a mature, cash-generative, but structurally declining pharmaceutical business layered with one genuine growth engine. Its Established Brands segment — nearly 60% of revenue — behaves like a long-duration, slowly amortizing annuity: durable because of global brand recognition and prescriber habit, but shrinking every year as generic competition and pricing policy erode it from the edges. Women's Health provides relative stability through real clinical switching costs in contraception and fertility, while Biosimilars, though still a modest share of revenue, is the only segment growing and represents the clearest path to offsetting established-brands erosion over time.

The defining strategic constraint is the debt inherited from the 2021 Merck spinoff, which has pushed management to slash the dividend by roughly 90%, divest non-core assets like Jada, and prioritize deleveraging above nearly everything else. For investors, Organon's moat is real but modest — rooted in manufacturing scale, regulatory complexity, and brand stickiness rather than patent exclusivity — and the central question going forward is whether biosimilars growth and disciplined cost management can bring leverage toward the 4.0x target before established-brands decline compounds further.